



Universiteit
Leiden

The Netherlands

Chemokines in atherosclerotic lesion development and stability : from mice to man

Jager, S.C.A. de

Citation

Jager, S. C. A. de. (2008, October 23). *Chemokines in atherosclerotic lesion development and stability : from mice to man*. Faculty of Science, Leiden University|Department of Biopharmaceutics, Leiden Amsterdam Center for Drug Research. Retrieved from <https://hdl.handle.net/1887/13158>

Version: Corrected Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/13158>

Note: To cite this publication please use the final published version (if applicable).

6

The CXCR3 Antagonist NBI-74330 Attenuates Atherosclerotic Plaque Formation in LDL Receptor Deficient Mice



Eva J.A. van Wanrooij¹, Saskia C.A. de Jager¹, Thomas van Es¹, Paula de Vos¹, Helen L. Birch², David A. Owen², Robbert J. Watson², Erik A.L. Biessen¹, Gayle A. Chapman², Theo J.C. van Berkel¹, Johan Kuiper¹

Arterioscler Thromb Vasc Biol. 2008;28(2):251-7

Abstract

Objective: The chemokine receptor CXCR3 is implicated in migration of leukocytes to sites of inflammation. Antagonizing CXCR3 may be a strategy to inhibit inflammation induced leukocyte migration and subsequently reduce atherosclerosis. We used the CXCR3 specific antagonist NBI-74330 to block CXCR3 mediated signalling in peritonitis and diet-induced atherosclerosis.

Methods and results: Antagonizing CXCR3 with NBI-74330 resulted in a significant reduction in CD4⁺ T cell and macrophage migration to the peritoneal cavity, which was as shown in ex-vivo migration studies totally CXCR3 dependent. Atherosclerotic lesion formation in the aortic valve leaflet area and the entire aorta was significantly inhibited in NBI-74330 treated mice. Lymph nodes draining from the aortic arch were significantly smaller in treated mice and were enriched in regulatory T cells and contained less activated T cells, while the markers for regulatory T cells within the lesion was enhanced after NBI-74330 treatment.

Conclusions: This study shows for the first time that treatment with a CXCR3 antagonist results in attenuating atherosclerotic lesion formation by blocking direct migration of CXCR3⁺ effector cells from the circulation into the atherosclerotic plaque and by beneficially modulating the inflammatory response in the lesion and the lymph nodes draining from the atherosclerotic lesion.

Introduction

Atherosclerosis is a progressive multi-factorial disease of the larger arteries characterized by cholesterol deposition, leukocyte influx, cell death and fibrosis. In recent years it has become increasingly clear that next to a lipid storage disorder, atherosclerosis can be considered as an ongoing inflammatory process within the vasculature^{1,2}. Migration of leukocytes into the vessel wall is an essential step in atherosclerotic lesion formation and progression, and chemokines are defined as key regulators of this process^{3,4}. Chemokine receptors are trans-membrane spanning, G-protein-coupled receptors which are classified by the position of the N-terminal cysteins (CC, CXC, C, CXXXC). They play an important role in the recruitment, migration and trafficking of immune cells to sites of inflammation. An increasing amount of evidence underscores the relevance of chemokines in the pathogenesis of atherosclerosis^{5,6,7,8-10}.

The chemokine receptor CXCR3 is expressed on different types of leukocytes, including T cells, B cells, natural killer (T) cells and monocytes¹¹⁻¹⁴. Its expression is highly induced upon CD4 T cell activation and is preferentially expressed on activated auto-reactive T cells¹⁵. Antibody-mediated blockade of CXCR3 results in a decreased recruitment of Th1 cells to sites of inflammation¹⁶. CXCR3 has 3 known ligands; MIG (monokine induced by IFN- γ (CXCL9)), IP-10 (IFN γ -inducible protein, (CXCL10)) and ITAC (IFN γ -inducible T-cell α -chemoattractant (CXCL11)). The expression of these ligands is highly inducible by interferon- γ (IFN γ), and associated with several inflammatory disorders. Recent publications point towards a prominent role for CXCR3 mediated migration of inflammatory cells in atherosclerosis. Human atherosclerotic lesions express high amounts of all three CXCR3 ligands¹⁷. Targeted deletion of CXCR3 in ApoE deficient (ApoE^{-/-}) mice resulted in decreased lesion formation in the abdominal aorta⁵. Furthermore, deletion of the CXCR3 ligand CXCL10 in ApoE^{-/-} mice resulted in decreased lesion formation by reducing the migration of CD4 effector T cells to the atherosclerotic plaque¹⁸.

Blockade of CXCR3 mediated migration could provide a potential strategy to reduce leukocyte migration to sites of inflammation and in this way attenuate atherosclerotic lesion formation. We describe that the highly specific CXCR3 antagonist NBI-74330 inhibits cell migration and diet induced atherosclerosis in LDL receptor deficient mice.

Material and methods

Determination of appropriate *in vivo* dosage of NBI-74330

The quinazolinone-derived CXCR3 antagonist NBI-74330 was synthesized as described by Medina *et al* (Patent WO02083143, U.S.A., 2002 Oct 24). Mice were treated with NBI-74330 in 0.1% Na Docusate in 0.5% 400Cp Methylcellulose and serum concentration at indicated time points were determined using LC-MS-MS. Serum was subjected to protein precipitation prior to analysis. HPLC mobile phase consisted of H₂O with 0.1% (v/v) formic acid and Acetonitrile with 0.1% (v/v) formic acid using a gradient profile.

Peritonitis induced migration and mobility assay

LDLr^{-/-} mice were treated with a subcutaneous injection of 100 mg/kg NBI-74330 (n=6) or vehicle (n=5) for 6 days. At day 2, all mice were injected intra-peritoneally with sterile 3% (w/v) Brewers thioglycolate solution. Peritoneal cells were isolated by peritoneal cavity lavage with PBS and counted and phenotyped by flow cytometry at day 6. Migration capacity of the isolated peritoneal cells in response to CXCL10 (100ng/ml), and the chemotactic peptide FMLP (1 μ M) was quantified using a chemokinesis assay¹⁹.

Atherosclerosis experiments

Female LDLr^{-/-} mice, 10 weeks old (n=8-12 per group), were fed a Western-type diet containing 0.25 % cholesterol and 15% cocoa butter two weeks before collar placement²⁰. Mice were treated with a subcutaneous injection of 100 mg/kg NBI-74330 every day during the entire experiment. After 8 weeks of Western-type diet and treatment, the mice were sacrificed and organs were harvested for histology, FACS and RNA isolation. Blood samples were collected by tail bleeding from non-fasted animals and concentrations of serum cholesterol and triglycerides were determined using enzymatic colorimetric procedures.

Histological analysis

Cryostat sections of the aortic root (10 µm) were collected and stained with Oil-red-O. Lesion size was determined in 5 sections of the aortic valve leaflet area. Corresponding sections on separate slides were stained immunohistochemically with an antibody directed against a macrophage specific antigen (MOMA-2, monoclonal rat IgG2b, diluted 1:50). Goat anti-rat IgG-AP (dilution 1:100) was used as secondary antibody and NBT-BCIP as enzyme substrates. Masson trichrome staining (Sigma Diagnostics) was used to visualize collagen (blue staining). TGF-β was stained with a polyclonal rabbit antibody (Santa Cruz, USA) and biotinylated goat anti rabbit (Dako cytomatics, The Netherlands) was used as a secondary antibody with Nova Red as enzyme substrate (Vector Laboratories).

Real time PCR assays

Total RNA was isolated from aortic arch and collar induced atherosclerotic plaques and was DNase treated. Quantitative gene expression analysis was performed on an ABI PRISM 7500 (Applied Biosystems, Foster City, CA) using SYBR Green technology. PCR primers (Supplemental Table I, page 109) were designed using Primer Express 1.7 software with the manufacturer's default settings (Applied Biosystems). Acidic ribosomal phosphoprotein PO (36B4) and hypoxanthine phosphoribosyl transferase (HPRT) were used as housekeeping genes.

Flow cytometry

Leukocytes from whole blood and spleen were isolated by density gradient centrifugation with Lympholyte (Cedarlane Laboratories, Hornby, Ontario, Canada). Cell suspensions from spleen, blood, lymph nodes draining from the aortic arch and peritoneal cavity were stained for surface markers (0.2 µg Ab/300.000 cells) and subsequently subjected to flow cytometric analysis (FACS). Antibodies were purchased from Immunoscource (Belgium). All data were acquired on a FACSCalibur and were analyzed with CELLQuest software (BD Biosciences).

Statistical analysis

Values are expressed as mean ± SEM unless indicated otherwise. Two-tailed student's T-test was used to compare normally distributed data between two groups of animals. Mann-Whitney test was used to compare not normally distributed data. A probability value of $p < 0.05$ was considered to be significant for both tests.

Results

In vivo use of NBI-74330

NBI-74330 is a small molecular high affinity CXCR3 antagonist that is a potent inhibitor of CXCR3 ligand binding with a K_i in the low nanomolar range (~8nM). *In vitro* data have shown that it inhibits CXCL10 and ITAC induced calcium mobilization at concentrations below 10 nM²¹. A formulation of NBI-74330 was constructed using 1% Na Docusate in 0.5% 400Cp Methylcellulose. We tested the optimal dosing of this formulation *in vivo* and found that daily dosage of 100 mg/kg via subcutaneous injections resulted in serum

concentrations of approximately $1\mu\text{M}$ (Figure 1). This concentration is sufficient to fully block the CXCR3 receptor *in vivo*.




Figure 1: Daily s.c. injections of 100 mg/kg NBI-74330 result in serum levels sufficient to fully antagonize CXCR3 *in vivo*. A formulation of NBI-74330 was constructed using 1% Na Doc in 0.5% 400Cp Methylcellulose and the mice ($n=3$) were treated with 100 mg/kg compound every day for 5 days. Serum levels were determined at indicated time points using LC-MS-MS. Dotted line indicates $\sim K_i$.




Figure 2: A) Recruitment of cells to the peritoneal cavity was reduced by 56% after NBI-74330 treatment (left panel). The percentage of CD4⁺ T cells and macrophages (F4/80⁺, Gr-1^{low}) present in the peritoneal cavity was significantly decreased in mice treated with NBI-74330 compared to control treated mice. (right panel, error bars represent SEM, *, $p < 0.05$, **, $p < 0.01$). B) Migration in response to CXCL10 and FMLP (positive control). (Error bars represent SD, ***, $p < 0.001$ compared to cells from control mice cultured with 100ng/ml CXCL10, ###: $p < 0.001$ compared to cells from control mice cultured with 100 ng/ml CXCL10, \$: $p < 0.01$, \$\$\$ $p < 0.001$ FMLP versus control stimulated cells).

The CXCR3 antagonist NBI-74330 inhibits CD4 T cell and macrophage migration during thioglycollate induced peritonitis

To show the *in vivo* capacity of NBI-74330 to antagonize CXCR3 mediated cell migration, we used a peritonitis model. In this model, leukocytes migrate to the peritoneal cavity in response to a single intraperitoneal thioglycollate challenge. Female LDLr^{-/-} mice were treated with NBI-74330 or control for 6 days. At day 2, in all mice peritonitis was induced and 5 days later the number of cells present in the peritoneum was quantified. A significant 56% reduction in leukocyte recruitment could be observed after 5 days in NBI-74330 treated mice compared to control treated mice (Figure 2A, $p=0.01$). FACS analysis of the isolated peritoneal cells showed that this reduction was mainly due to reduced migration of CD4⁺ T cells and macrophages (Figure 2A).

To investigate the capacity of the isolated peritoneal cells from control and NBI-74330 treated mice to migrate in response to the CXCR3 ligand CXCL10 we performed an *ex vivo* mobility study. Isolated peritoneal cells from control and treated mice were allowed to accumulate at the lower end of a 96-well culture plate and migration in response to 100ng/ml CXCL10 and fMLP (positive control) was then assessed (Figure 2B). Peritoneal cells isolated from mice treated with vehicle for 6 days had a clear migratory response when exposed to 100 ng/ml CXCL10 and this effect was completely reversed by the *in vitro* addition of NBI-74330 to the culture medium. Cells isolated from *in vivo* NBI-74330 treated mice during the thioglycollate challenge were not able to respond to CXCL10. Their capability to migrate while exposed to the general chemotactic peptide fMLP was not different from control treated mice. These findings clearly show that the reduced migration towards thioglycollate induced peritonitis by NBI-74330 treatment is the result of an effective *in vivo* blockade of CXCR3.

Atherosclerotic lesion formation in LDLr^{-/-} mice is attenuated by antagonizing CXCR3

LDLr^{-/-} mice on a Western type diet were used as model for atherosclerosis and mRNA expression of CXCR3 during lesion formation was monitored in the aortic arch at different time points of western type diet feeding. A significant increase was observed in CXCR3 mRNA expression after 9 weeks of diet, indicating initial influx of CXCR3 expressing leukocytes (Figure 3). We then assessed the effect of NBI-74330 treatment on atherosclerotic lesion formation.




Figure 3: mRNA expression of CXCR3 is significantly upregulated in the aortic arch of LDLr^{-/-} mice on Western typed diet feeding. mRNA was isolated from the aortic arch of LDLr^{-/-} mice using the GTC method and expression of CXCR3 is expressed relative to 36B4 and HPRT, and subsequently related to the expression in mice on chow diet. An unpaired Student t test was applied to test whether CXCR3 mRNA levels were significantly different from the mRNA levels in chow fed animals (week 0) (* $p < 0.05$, $n = 6$ per time point).

Female LDLr^{-/-} mice were fed a Western-type diet and received daily subcutaneous injections of 100 mg/kg NBI-74330 or vehicle. No difference was observed in serum cholesterol and triglyceride levels between control and treated animals (supplemental table 2, page 109). Fig. 4 shows representative sections of control treated (Figure 4A) and NBI-74330 treated (Figure 4B) mice. Atherosclerotic lesion formation in the aortic valve leaflet area was significantly inhibited in mice treated with NBI-74330 ($536 \times 10^3 \mu\text{m}^2$ vs. $391 \times 10^3 \mu\text{m}^2$, $p < 0.05$). Relative macrophage staining (MoMa-2) was comparable in plaques from control and treated animals, as well as the relative collagen content as determined by Masson trichrome staining (Supplemental Figure 1, page 109). We also quantified the lesion area in the aorta of control and NBI-74330 treated mice by en face staining with Oil red O. Representative pictures of control (Figure 4D) and NBI-74330 treated aortas (Figure 4E) are shown. NBI-74330 treatment resulted in a 53 % reduction in lesion formation compared to control treated mice ($18 \pm 2\%$ vs. $8 \pm 2\%$, $p = 0.01$).




Figure 4: Atherosclerotic lesion formation is significantly inhibited in mice treated with NBI-74330. Representative photomicrographs of oil red O stained cross sections of the aortic root of control treated mice (A) and NBI-74330 treated mice (B) are shown. A significant reduction in plaque size was found as compared to control ($p = 0.03$, $n = 11$ control, $n = 7$ treated) (C). Relative plaque area was quantified in en face pinned aortas. Representative pictures are shown for control (D) and NBI-74330 treated mice (E). Lesion formation is significantly inhibited by NBI-74330 treatment by 53% ($p = 0.01$, $n = 11$ control, $n = 7$ treated).

CXCR3 antagonist treated mice have smaller draining lymph nodes and a beneficial regulatory/effector T cell balance

Recent publications suggest a role for CXCR3 in the migration of effector cells towards the site of inflammation^{18,22,23}. We isolated the lymph nodes draining from the aortic arch of LDLr^{-/-} mice after 8 weeks of Western type diet and control or NBI-74330 treatment. Treatment with NBI-74330 resulted in a 64% reduction in cell numbers in lymph nodes draining from the aortic arch (Figure 5A). Characterization of the isolated cell population was performed using FACS. A specific enrichment in CD25^{high} (3.1% in

controls vs. 10.1% in treated) cells within the CD4⁺ T cell population was observed in NBI-74330 treated mice (Figure 5B, $p<0.05$). The CD4⁺CD25^{high} regulatory T cells represent 0.6% of the total lymph cell population in controls (data not shown). This increase in regulatory T cells was accompanied by an increase in the expression of CD62L on CD4⁺ cells ($p<0.001$), suggesting a reduction in the activation state of effector T cells. These effects were restricted to the lymph nodes draining from the aortic arch, as were not observed in spleen or the circulating white blood cell population.




Figure 5: Draining lymph nodes from the aortic arch of NBI-74330 treated mice are smaller in size and contain less activated and more regulatory T cells. Draining lymph nodes were isolated from control and NBI-74330 treated mice after 8 weeks of western type diet feeding. Single cell suspensions were prepared and total cell number was quantified. NBI-74330 treatment ($n=7$) resulted in a 64% decrease in cell number compared to control ($n=11$). (A, Error bars represent SEM, $*$: $p<0.05$). Flow cytometry was used to assess the relative amount of CD25^{high} regulatory cells, and the percentage of CD62L^{high} cells within the CD4⁺ positive population. (B, Error bars represent SEM, $n=6$ per group, $*$: $p<0.05$, $***$: $p<0.001$).




Figure 6: Atherosclerotic plaques from NBI-74330 treated mice express increased levels of regulatory T cell associated molecules. A-C: Sections of the aortic leaflet area were stained for TGF-β using anti-TGF-β antibodies. We then quantified the TGF-β positive area relative to total plaque area. Treatment with NBI-74330 (B) resulted in a significant increase in relative TGF-β positive area (red staining) as compared to control (A). Data are expressed as mean $\pm$ SEM, $n=11$ control, $n=7$ treated). D: mRNA expression of different genes isolated from collar induced atherosclerotic plaques (8 weeks) is expressed relative to 36B4 and HPRT, and subsequently related to the expression in control mice. White bars represent control mice; black bars represent NBI-74330 treated mice. An unpaired Student *t* test was applied to test if mRNA levels were significantly different from the mRNA levels in chow fed animals ($n=5-10$ per group) ($*p<0.05$).

Plaques from mice treated with NBI-74330 express more genes associated with regulatory T cells

To determine whether the local reduction in effector cells and the increase in regulatory T cell phenotype resulted in a resembling cytokine profile inside the atherosclerotic plaque we stained for the regulatory T cell cytokine TGF- β . Representative slides are shown for control (Figure 6A) and NBI-74330 treated (Figure 6B) mice. A significant increase was observed in the relative expression of TGF β in the plaque of mice treated with NBI-74330 compared to control (Figure 6C). We performed QPCR on atherosclerotic plaques isolated from the carotid artery after collar induced atherosclerosis from both control and treated mice and determined the expression of the regulatory T cell associated genes Foxp3, CD25 and CTLA-4 (Figure 6D). The expression of Foxp3 was 2.5 fold upregulated ($p < 0.05$), and the expression of CTLA-4 was 6 fold upregulated ($p < 0.05$) compared to expression in control treated mice. The expression of CD25 showed a trend towards an increased expression, but this was not significant.

Discussion

Evidence is building that CXCR3 mediated cell migration plays an important role in several (auto-) immune diseases²⁴⁻²⁷. CXCR3 positive cells enter the site of inflammation followed by a local upregulation of CXCR3 expression. These CXCR3 positive cells are attracted by the 3 known ligands, CXCL9, 10 and 11, and it was shown that these ligands are highly expressed in atherosclerotic lesions¹⁷. In this study we used the highly specific CXCR3 antagonist NBI-74330 to block CXCR3 mediated signaling and migration. Firstly, we showed the *in vivo* capacity of this compound to reduce cell migration to a site of inflammation using a thioglycollate induced peritonitis model. Total leukocyte migration to the peritoneal cavity was reduced by 56% upon daily treatment with NBI-74330. The reduction in total cell migration was the consequence of a reduction in the number of CD4⁺ T cells and macrophages to the peritoneal cavity. The observed decrease in migration was the result of selective blockage of CXCR3, as shown by a subsequent *ex vivo* mobility assay. Peritoneal cells isolated from control mice were able to migrate in response to both CXCL10 and FMLP. Cells isolated from mice that received NBI-74330 during the induction of peritonitis were not responsive to CXCL10, but were still capable of migrating in response to an FMLP stimulus.

After we established the *in vivo* efficacy of the compound, we used LDL receptor deficient mice to test the effect of antagonizing CXCR3 on atherosclerotic lesion formation. We show that the expression of CXCR3 is upregulated in the aortic arch of LDLr^{-/-} mice fed a western type diet for 9 weeks. This indicates that CXCR3 positive leukocytes migrate to the developing atherosclerotic plaque. It was shown that CXCR3 deficient mice on an ApoE background show reduced lesion burden compared to control ApoE mice. In addition, mice lacking CXCL10, the main ligand for CXCR3, show decreased atherogenesis compared to control ApoE mice. These are interesting observations, clearly suggesting that CXCR3 is involved in the disease initiation and progression of atherosclerosis in ApoE deficient mice. However, these mice lack the expression of these proteins throughout their development and compensating mechanisms to overcome this deficiency may have taken place.

In this study, we use the compound NBI-74330, a highly specific low molecular weight CXCR3 antagonist, to investigate the effect of antagonizing CXCR3 in a diet induced model for atherosclerosis. Treatment with NBI-74330 resulted in a significant decrease in atherosclerotic lesion formation at the aortic valve leaflet area as well as the total aorta. We observed a more pronounced decrease in lesion size in the aorta compared to the valve leaflet area. In their study with CXCR3/ApoE double deficient animals, Veillard *et al.* also showed a difference in lesion formation between these two sites, since they observed a significant decrease in the degree of lesion formation in

the descending aorta was observed, but no effect in the aortic sinus. They suggest a more prominent role for CXCR3 in the initial stages of lesion formation. Our findings strengthen this idea as we had quite large and advanced lesions in the valves, while the lesion burden in the aorta was more moderate.

As shown, CXCR3 mediates the migration of effector cells to the site of inflammation. Absence of CXCR3 or its main ligand CXCL10 in mice on an ApoE background resulted in an induction of regulatory T cells markers within the atherosclerotic plaque but not in lymph nodes or circulation. Our experiments clearly show that administration of a pharmacologically active CXCR3 antagonist results in smaller lymph nodes draining from the aortic arch compared to control treated mice. The activation state of T cells is decreased and regulatory phenotype is enhanced in these lymph nodes of NBI-74330 treated mice. When LDLr^{-/-} mice are fed a Western type diet, the lymph nodes draining from the aortic arch increase in size due to local inflammatory signals. Administering a CXCR3 antagonist clearly reduced the migration of leukocytes to the lymphatic sites draining to the site of inflammation. This indicates that not only direct migration of effector cells from the circulation to the atherosclerotic plaque is inhibited, but that also migration to the draining lymph system is beneficially modulated. Possibly CXCL9 and 11 are involved in this process, because no increase in regulatory T cells was observed in lymph cells isolated from CXCL10 deficient mice. Furthermore we observe that NBI-74330 treated mice have an increased number of CD4⁺CD25^{high} regulatory T cells in the lymph nodes draining directly from the aortic arch²⁸ and an increased expression of the regulatory T cell markers Foxp3, CTLA-4 and CD25 within the atherosclerotic plaque and increased TGFβ levels. This indicates that regulatory T cells are the likely source of the observed increase in (surface bound) TGF-β expression within the atherosclerotic plaque²⁹⁻³⁴ and inhibit the local effector T cell responses.

We hypothesize that the observed reduction in lesion formation and the accompanying induction of a regulatory T cell phenotype results from a reduction in migration of effector cells to the atherosclerotic plaque and to the draining lymph nodes, which leads to a relative induction of anti-inflammatory and regulatory cells. Eventually, due to the continuing exposure to antigens such as oxLDL or heat shock proteins, the ongoing attraction of leukocytes via other pathways than CXCR3 will facilitate the process of lesion formation. The blockade of CXCR3 thus provides a “lag-time” in this response.

It is clear that selective blockade of CXCR3 migration *in vivo* using NBI-74330 provides an attractive way to beneficially balance the immune response in an auto-inflammatory situation such as atherosclerosis. A possible drawback of interfering with CXCR3 mediated migration could be a potentially hampered immune response against invading pathogens. For example, lung infection with *B. Bronchiseptica* results in strong upregulation of CXCR3 ligands and influx of CXCR3⁺ cells. However, CXCR3 deficient mice do not show increased mortality to this pathogen. Furthermore, Chackavarty *et al.* have showed that, CXCR3 deficient mice are more resistant to *Mycobacterium tuberculosis* infection³⁵. CXCR3 is also associated with cellular influx into CMV infected liver. Infection of the liver with CMV attracts CXCR3⁺ CD8⁺ cells that contribute to the protective response to the virus but these cells are not exclusive required for its clearance³⁶. Based on these observations treatment with a selective CXCR3 antagonist is unlikely to result in severe infections with pathogens.

Small molecular antagonists are the preferential and most widely used drugs and have clear advantages over protein or antibody formulations. We conclude that this study shows for the first time that a small molecular CXCR3 antagonist inhibits lesion formation in an animal model for atherosclerosis. This study therefore provides evidence that CXCR3 antagonists can be a possible new therapeutic strategy to counteract the development of atherosclerosis or other (auto)-immune diseases.

Acknowledgments


This research was supported by a grant from the Netherlands Heart Foundation (NHF 2000T040, 2003T201) and a grant from the Netherlands Organisation for Scientific Research (NWO 050-10-014).

References

1. Hansson GK, Libby P. The immune response in atherosclerosis: a double-edged sword. *Nat Rev Immunol*. 2006;6:508-519.
2. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. *N Engl J Med*. 2005;352:1685-1695.
3. Weber C, Schober A, Zernecke A. Chemokines: key regulators of mononuclear cell recruitment in atherosclerotic vascular disease. *Arterioscler Thromb Vasc Biol*. 2004;24:1997-2008.
4. Liehn EA, Zernecke A, Postea O, Weber C. Chemokines: Inflammatory mediators of atherosclerosis. *Arch Physiol Biochem*. 2006;112:229-238.
5. Veillard NR, Steffens S, Pelli G, Lu B, Kwak BR, Gerard C, Charo IF, Mach F. Differential influence of chemokine receptors CCR2 and CXCR3 in development of atherosclerosis in vivo. *Circulation*. 2005;112:870-878.
6. Boisvert WA, Curtiss LK, Terkeltaub RA. Interleukin-8 and its receptor CXCR2 in atherosclerosis. *Immunol Res*. 2000;21:129-137.
7. Trogan E, Feig JE, Dogan S, Rothblat GH, Angeli V, Tacke F, Randolph GJ, Fisher EA. Gene expression changes in foam cells and the role of chemokine receptor CCR7 during atherosclerosis regression in ApoE-deficient mice. *Proc Natl Acad Sci U S A*. 2006;103:3781-3786.
8. van Wanrooij EJ, Happe H, Hauer AD, de Vos P, Imanishi T, Fujiwara H, van Berkel TJ, Kuiper J. HIV entry inhibitor TAK-779 attenuates atherogenesis in low-density lipoprotein receptor-deficient mice. *Arterioscler Thromb Vasc Biol*. 2005;25:2642-2647.
9. Brauersreuther V, Zernecke A, Arnaud C, Liehn EA, Steffens S, Shagdarsuren E, Bidzhekov K, Burger F, Pelli G, Luckow B, Mach F, Weber C. Ccr5 but not Ccr1 deficiency reduces development of diet-induced atherosclerosis in mice. *Arterioscler Thromb Vasc Biol*. 2007;27:373-379.
10. Kraaijeveld AO, de Jager SC, van Berkel TJ, Biessen EA, Jukema JW. Chemokines and Atherosclerotic Plaque Progression: Towards Therapeutic Targeting? *Curr Pharm Des*. 2007;13:1039-1052.
11. Qin S, Rottman JB, Myers P, Kassam N, Weinblatt M, Loetscher M, Koch AE, Moser B, Mackay CR. The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions. *J Clin Invest*. 1998;101:746-754.
12. Henneken M, Dorner T, Burmester GR, Berek C. Differential expression of chemokine receptors on peripheral blood B cells from patients with rheumatoid arthritis and systemic lupus erythematosus. *Arthritis Res Ther*. 2005;7:R1001-1013.
13. Johnston B, Kim CH, Soler D, Emoto M, Butcher EC. Differential chemokine responses and homing patterns of murine TCR alpha beta NKT cell subsets. *J Immunol*. 2003;171:2960-2969.
14. Janatpour MJ, Hudak S, Sathe M, Sedgwick JD, McEvoy LM. Tumor necrosis factor-dependent segmental control of MIG expression by high endothelial venules in inflamed lymph nodes regulates monocyte recruitment. *J Exp Med*. 2001;194:1375-1384.
15. Sallusto F, Lanzavecchia A, Mackay CR. Chemokines and chemokine receptors in T-cell priming and Th1/Th2-mediated responses. *Immunol Today*. 1998;19:568-574.
16. Xie JH, Nomura N, Lu M, Chen SL, Koch GE, Weng Y, Rosa R, Di Salvo J, Mudgett J, Peterson LB, Wicker LS, DeMartino JA. Antibody-mediated blockade of the CXCR3 chemokine receptor results in diminished recruitment of T helper 1 cells into sites of inflammation. *J Leukoc Biol*. 2003;73:771-780.
17. Mach F, Sauty A, Iarossi AS, Sukhova GK, Neote K, Libby P, Luster AD. Differential expression of three T lymphocyte-activating CXC chemokines by human atheroma-associated cells. *J Clin Invest*. 1999;104:1041-1050.
18. Heller EA, Liu E, Tager AM, Yuan Q, Lin AY, Ahluwalia N, Jones K, Koehn SL, Lok VM, Aikawa E, Moore KJ, Luster AD, Gerszten RE. Chemokine CXCL10 promotes atherogenesis by modulating the local balance of effector and regulatory T cells. *Circulation*. 2006;113:2301-2312.
19. Strobel ES, Mobest D, von Kleist S, Dangel M, Ries S, Mertelsmann R, Henschler R. Adhesion and migration are differentially regulated in hematopoietic progenitor cells by cytokines and extracellular matrix. *Blood*. 1997;90:3524-3532.
20. von der Thüsen JH, van Berkel TJ, Biessen EA. Induction of rapid atherogenesis by perivascular carotid collar placement in apolipoprotein E-deficient and low-density lipoprotein receptor-deficient mice. *Circulation*. 2001;103:1164-1170.
21. Heise CE, Pahuja A, Hudson SC, Mistry MS, Putnam AL, Gross MM, Gottlieb PA, Wade WS, Kiankarimi M, Schwarz D, Crowe P, Zlotnik A, Alleva DG. Pharmacological characterization of CXCR3 chemokine receptor 3 ligands and a small molecule antagonist. *J Pharmacol Exp Ther*. 2005;313:1263-1271.
22. Christensen JE, de Lemos C, Moos T, Christensen JP, Thomsen AR. CXCL10 is the key ligand for CXCR3 on CD8+ effector T cells involved in immune surveillance of the lymphocytic choriomeningitis virus-infected central nervous system. *J Immunol*. 2006;176:4235-4243.
23. Dufour JH, Dziejman M, Liu MT, Leung JH, Lane TE, Luster AD. IFN-gamma-inducible protein 10 (IP-10; CXCL10)-deficient mice reveal a role for IP-10 in effector T cell generation and trafficking. *J Immunol*. 2002;168:3195-3204.
24. Balashov KE, Rottman JB, Weiner HL, Hancock WW. CCR5(+) and CXCR3(+) T cells are increased in multiple sclerosis and their ligands MIP-1alpha and IP-10 are expressed in demyelinating brain lesions. *Proc Natl Acad Sci U S A*. 1999;96:6873-6878.
25. Norii M, Yamamura M, Iwashashi M, Ueno A, Yamana J, Makino H. Selective recruitment of CXCR3+ and CCR5+ CCR4+ T cells into synovial tissue in patients with rheumatoid arthritis. *Acta Med Okayama*. 2006;60:149-157.
26. Sinden E, Patzold T, Ossege LM, Gisevius A, Malin JP. Expression of chemokine receptor CXCR3 on cerebrospinal fluid T-cells is related to active MRI lesion appearance in patients with relapsing-remitting multiple sclerosis. *J Neuroimmunol*. 2002;131:186-190.

27. Tsubaki T, Takegawa S, Hanamoto H, Arita N, Kamogawa J, Yamamoto H, Takubo N, Nakata S, Yamada K, Yamamoto S, Yoshie O, Nose M. Accumulation of plasma cells expressing CXCR3 in the synovial sublining regions of early rheumatoid arthritis in association with production of Mig/CXCL9 by synovial fibroblasts. *Clin Exp Immunol.* 2005;141:363-371.
28. van Puijvelde GH, Hauer AD, de Vos P, van den Heuvel R, van Herwijnen MJ, van der Zee R, van Eden W, van Berkel TJ, Kuiper J. Induction of oral tolerance to oxidized low-density lipoprotein ameliorates atherosclerosis. *Circulation.* 2006;114:1968-1976.
29. Zheng SG, Wang J, Wang P, Gray JD, Horwitz DA. IL-2 is essential for TGF-beta to convert naive CD4+CD25- cells to CD25+Foxp3+ regulatory T cells and for expansion of these cells. *J Immunol.* 2007;178:2018-2027.
30. Luo X, Tarbell KV, Yang H, Pothoven K, Bailey SL, Ding R, Steinman RM, Suthanthiran M. Dendritic cells with TGF- β 1 differentiate naive CD4+CD25- T cells into islet-protective Foxp3+ regulatory T cells. *Proc Natl Acad Sci U S A.* 2007.
31. Peng Y, Laouar Y, Li MO, Green EA, Flavell RA. TGF-beta regulates in vivo expansion of Foxp3-expressing CD4+CD25+ regulatory T cells responsible for protection against diabetes. *Proc Natl Acad Sci U S A.* 2004;101:4572-4577.
32. Fantini MC, Becker C, Monteleone G, Pallone F, Galle PR, Neurath MF. Cutting edge: TGF-beta induces a regulatory phenotype in CD4+CD25- T cells through Foxp3 induction and down-regulation of Smad7. *J Immunol.* 2004;172:5149-5153.
33. Chen W, Jin W, Hardegen N, Lei KJ, Li L, Marinos N, McGrady G, Wahl SM. Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. *J Exp Med.* 2003;198:1875-1886.
34. Fantini MC, Becker C, Tubbe I, Nikolaev A, Lehr HA, Galle P, Neurath MF. Transforming growth factor beta induced FoxP3+ regulatory T cells suppress Th1 mediated experimental colitis. *Gut.* 2006;55:671-680.
35. Chakravarty SD, Xu J, Lu B, Gerard C, Flynn J, Chan J. The Chemokine Receptor CXCR3 Attenuates the Control of Chronic Mycobacterium tuberculosis Infection in BALB/c Mice. *J Immunol.* 2007;178:1723-1735.
36. Hokeness KL, Deweerd ES, Munks MW, Lewis CA, Gladue RP, Salazar-Mather TP. CXCR3-dependent recruitment of antigen-specific T lymphocytes to the liver during murine cytomegalovirus infection. *J Virol.* 2007;81:1241-1250.

Supplemental Figures and Tables



Supplemental figure 1: NBI-74330 treatment has no effect on relative macrophage and collagen content of atherosclerotic plaques. Plaque composition of NBI-74330 treated and control treated mice was determined using Masson Trichrome staining to visualize collagen (figure 4 A,B) or a macrophage specific antibody (MoMa-2) (figure 4 D,E, staining depicted in dark blue). Representative sections are shown for each group. Data are expressed as %: indicating the relative contribution of the collagen and macrophages area to the entire plaque area. No significant effects could be observed between control and treated animals ($n \geq 8$ per group).

Gene	Reverse primer	Forward primer
36B4	GGACCCGAGAAGACCTCCTT	GCACATCACTCAGAATTTCAATGG
CD25	CTTATATTGCAAATGTGGCACAATC	ATCAATCATCAGTGGGACAATCTG
CTLA-4	CGAGGTCCTGCACCAACTG	TCCATCACCATCGGTTTATGC
CXCR3	GCTGCTGTCCAGTGGGTTTT	AGTTGATGTTGAACAAGGCGC
FOXP3	GGAGCCGCAAGCTAAAAGC	TGCCTTCGTGCCCACTGT
HPRT	TTGCTCGAGATGTCATGAAGGA	AGCAGGTCAGCAAAGAAGCTTATAG

Supplemental Table 1: Real time PCR primers.

	Control mice	NBI-74330 treated mice
Total Cholesterol (mg/dl)	1142 $\pm$ 20	1101 $\pm$ 37
Triglycerides (mg/dl)	640 $\pm$ 12	615 $\pm$ 22
Weight (g)	28.2 $\pm$ 0.7	29.2 $\pm$ 1.2

Supplemental Table 2: Serum lipid levels at sacrifice.

* authors contributed equally to this study

1. Division of Biopharmaceutics, LACDR, Leiden, the Netherlands.
2. Cellular and Molecular Nutrition, Instituto de la Grasa, Sevilla, Spain.
3. Dept. of Molecular Biology and Genetics, Johns Hopkins University School of Medicine, Baltimore, U.S.A.
4. Experimental Vascular Pathology group, Department of Pathology, CARIM, Academic University Hospital Maastricht, the Netherlands.